These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 21842452

  • 1. Adverse effects and adherence to treatment of rifampicin 4 months vs isoniazid 6 months for latent tuberculosis: a retrospective analysis.
    Fresard I, Bridevaux PO, Rochat T, Janssens JP.
    Swiss Med Wkly; 2011; 141():w13240. PubMed ID: 21842452
    [Abstract] [Full Text] [Related]

  • 2. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
    Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI.
    Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
    [Abstract] [Full Text] [Related]

  • 3. Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center.
    Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE.
    Clin Infect Dis; 2017 Nov 29; 65(12):2105-2111. PubMed ID: 29020308
    [Abstract] [Full Text] [Related]

  • 4. Baseline abnormal liver function tests are more important than age in the development of isoniazid-induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection.
    Gray EL, Goldberg HF.
    Intern Med J; 2016 Mar 29; 46(3):281-7. PubMed ID: 26648478
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of latent tuberculosis infection: An update.
    Lobue P, Menzies D.
    Respirology; 2010 May 29; 15(4):603-22. PubMed ID: 20409026
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review.
    Kunst H, Khan KS.
    Int J Tuberc Lung Dis; 2010 Nov 29; 14(11):1374-81. PubMed ID: 20937175
    [Abstract] [Full Text] [Related]

  • 9. Reparation of Isoniazid and Rifampicin Combinatorial Therapy-Induced Hepatotoxic Effects by Bacopa monnieri.
    Evan Prince S, Udhaya LB, Sunitha PS, Arumugam G.
    Pharmacology; 2016 Nov 29; 98(1-2):29-34. PubMed ID: 27007136
    [Abstract] [Full Text] [Related]

  • 10. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital.
    Chung SJ, Lee H, Koo GW, Min JH, Yeo Y, Park DW, Park TS, Moon JY, Kim SH, Kim TH, Sohn JW, Yoon HJ.
    Sci Rep; 2020 Apr 15; 10(1):6462. PubMed ID: 32296096
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis factor blocker treatment.
    Bray MG, Poulain C, Dougados M, Gossec L.
    Joint Bone Spine; 2010 Mar 15; 77(2):135-41. PubMed ID: 20097592
    [Abstract] [Full Text] [Related]

  • 14. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis.
    Long MW, Snider DE, Farer LS.
    Am Rev Respir Dis; 1979 Jun 15; 119(6):879-94. PubMed ID: 110184
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy.
    Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, Klaassen CD, Gonzalez FJ, Ma X.
    Nat Med; 2013 Apr 15; 19(4):418-20. PubMed ID: 23475203
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR.
    J Eval Clin Pract; 2014 Oct 15; 20(5):685-91. PubMed ID: 25087583
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT, Lee JH.
    J Korean Med Sci; 2015 Feb 15; 30(2):167-72. PubMed ID: 25653488
    [Abstract] [Full Text] [Related]

  • 20. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ, Terry Beirn Community Programs for Clinical Research on AIDS, Adult AIDS Clinical Trials Group, Centers for Disease Control and Prevention.
    Clin Infect Dis; 2004 Aug 15; 39(4):561-5. PubMed ID: 15356822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.